@positivehealth ... I have not been treated for Rituximab and frankly don't want to be at this stage of my WM (started at IgM 2622, Neuropathy w/ AMA 1531). Brukinsa (Zanubrutinib) is a relatively newer (second generation) "targeted (chemo) drug" for WM. Imbruvica (Ibrutinib) was first generation, but it attacked other enzymes as well causing more side effects. BTK Inhibitors specifically bind with the BTK enzyme and therefore "inhibits" it. This attacks the IgM (cancerous) clonal B-cells, which are attacking the myelin-nerve sheathing in my feet (PN). Brukinsa is expected to cause fewer side effects.

Brukinsa is a 160mg pill (capsule) taken orally "twice" per day. It is highly regulated (strong) so it is not distributed through standard pharmacies. I mentioned earlier that it is 71.4% effective in treating peripheral neuropathy. After one month on Brukinsa my IgM dropped from 2454 to 2167 and my AMA (Anti-MAG) dropped from 1531 to normal (<900).